Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant.
We evaluated effects of graft transport time on outcomes after transplantation of 938 unrelated donor bone marrow (BM) or 507 peripheral blood progenitor cells (PBPC) in patients with acute or chronic leukemia and myelodysplastic syndrome (MDS). BM grafts were collected at 107 centers and PBPC, 89 centers. Median time from end of collection to infusion was 14 hours for BM and 15 hours for PBPC. Platelet recovery was less likely in BM recipients when the interval from end of collection to receipt at transplant center was >or=20 hours (odds ratio 0.47, P = .010) and when the interval from receipt to infusion was >or=6 hours (odds ratio 0.57, P = .001). Mortality rates were higher in recipients of HLA-matched BM when the interval from end of collection to receipt at transplant center was >or=20 hours (relative risk 2.67, P < .001) after adjustment for other significant prognostic factors. Mortality after HLA-mismatched BM transplants was not associated with transport time. Transport times had no demonstrable effect on outcomes after PBPC transplants. These data support a general review of current transport procedures, especially for BM grafts requiring longer transport time and every effort made to minimize time from collection to infusion.
Lazarus
Hillard M
HM
University Hospitals Case Medical Center, Cleveland, Ohio, USA.
Kan
Fangyu
F
Tarima
Sergey
S
Champlin
Richard E
RE
Confer
Dennis L
DL
Frey
Noelle
N
Gee
Adrian P
AP
Wagner
John E
JE
Horowitz
Mary M
MM
Eapen
Mary
M
D018070:Biological Specimen Banks / Q000592:standards*; D016026:Bone Marrow Transplantation / Q000379:methods / Q000401:mortality* / Q000592:standards; D003625:Data Collection; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000401:mortality* / Q000592:standards; D006648:Histocompatibility; D006801:Humans; D007938:Leukemia / Q000401:mortality / Q000628:therapy; D008297:Male; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D009190:Myelodysplastic Syndromes / Q000401:mortality / Q000628:therapy; D016017:Odds Ratio; D013997:Time Factors; D014019:Tissue Donors; D014186:Transportation / Q000592:standards*; D016896:Treatment Outcome
D019653:Myeloablative Agonists